FDA Greenlights Companion Diagnostic for Encorafenib Plus Cetuximab in BRAF V600E+ mCRC

The FDA has approved FoundationOne CDx for use as a companion diagnostic to determine patients with BRAF V600E–mutated metastatic colorectal cancer who may be candidates to receive encorafenib in combination with cetuximab.

Related Keywords

Lilly Erbitux ,Foundationone Cdx ,Eli Lilly ,Foundationone Liquidcdx ,Foundation Medicine Inc ,Drug Administration ,Accessed June ,Precision Medicine In Oncology ,News ,Colorectal Cancer ,Braf V600e Mutated Metastatic Colorectal Cancer ,Encorafenib ,Cetuximab ,Erbitux ,